Pharming Group N.V. Logo

Pharming Group N.V.

ISIN: NL0010391025 | Ticker: PHARM | LEI: 724500DCJ9MPG74JEH91
Sector: Health CareSub-Industry: Biotechnology
Country: Netherlands

About Pharming Group N.V.

Company Description

Pharming is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.

Our key strengths include the following:

- Sales growth of our commercialized asset.

- Proven rare-disease commercialization capabilities.

- Internal pipeline of product candidates.

- Transgenic Production Platform Technology.

- Data exclusivity, know-how and intellectual property.

Year founded

1988

Served area

Worldwide

Headquarters

Darwinweg 24, 2333 Leiden, Zuid-Holland – Netherlands

Financial statements

Download as Excel
Line item in (usd) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets 255,915,000.00 418,453,000.00 397,315,000.00 425,797,000.00
Noncurrent Assets 136,479,000.00 155,241,000.00 147,871,000.00 148,297,000.00
Property Plant And Equipment 9,591,000.00 12,226,000.00 13,222,000.00 10,392,000.00
Intangible Assets Other Than Goodwill 79,403,000.00 94,083,000.00 83,834,000.00 75,121,000.00
Investment Accounted For Using Equity Method 6,177,000.00 7,118,000.00 7,201,000.00 2,501,000.00
Noncurrent Prepayments 0.00 0.00 194,000.00 228,000.00
Deferred Tax Assets 32,061,000.00 31,877,000.00 21,216,000.00 22,973,000.00
Noncurrent Financial Assets At Fair Value Through Profit Or Loss N/A N/A 0.00 6,827,000.00
Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income 0.00 0.00 1,449,000.00 403,000.00
Noncurrent Restricted Cash And Cash Equivalents 2,543,000.00 510,000.00 812,000.00 1,099,000.00
Current Assets 119,435,000.00 263,212,000.00 249,444,000.00 277,500,000.00
Inventories 16,223,000.00 21,157,000.00 27,310,000.00 42,326,000.00
Trade And Other Current Receivables 28,864,000.00 35,901,000.00 29,983,000.00 27,619,000.00
Cash and cash equivalents 74,348,000.00 205,159,000.00 191,924,000.00 207,342,000.00
Current Restricted Cash And Cash Equivalents 0.00 995,000.00 227,000.00 213,000.00
Equity And Liabilities 255,915,000.00 418,453,000.00 397,315,000.00 425,797,000.00
Equity 117,388,000.00 183,435,000.00 192,916,000.00 204,638,000.00
Issued Capital 7,226,000.00 7,312,000.00 7,429,000.00 7,509,000.00
Retained Earnings -340,715,000.00 -295,621,000.00 -273,167,000.00 -256,431,000.00
Share Premium 441,951,000.00 447,130,000.00 455,254,000.00 462,297,000.00
Other Reserves 8,926,000.00 24,614,000.00 3,400,000.00 -8,737,000.00
Noncurrent Liabilities 24,273,000.00 158,169,000.00 157,628,000.00 161,461,000.00
Other Noncurrent Financial Liabilities 19,380,000.00 212,000.00 165,000.00 0.00
Noncurrent Portion Of Noncurrent Bonds Issued 0.00 149,727,000.00 139,007,000.00 131,618,000.00
Current Liabilities 114,254,000.00 76,849,000.00 46,771,000.00 59,698,000.00
Trade And Other Current Payables 40,646,000.00 47,666,000.00 42,473,000.00 54,465,000.00
Other Current Financial Liabilities 20,000,000.00 25,000,000.00 0.00 N/A
Current Derivative Financial Liabilities 301,000.00 181,000.00 0.00 N/A
Current Bonds Issued And Current Portion Of Noncurrent Bonds Issued 0.00 2,040,000.00 1,879,000.00 1,768,000.00
Line item in (usd) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 212,174,000.00 198,871,000.00 205,622,000.00
Other Income 1,829,000.00 2,620,000.00 14,523,000.00
Profit Loss From Operating Activities 76,256,000.00 13,561,000.00 18,233,000.00
Finance Income 715,000.00 14,894,000.00 4,485,000.00
Finance Costs 33,308,000.00 6,185,000.00 5,463,000.00
Profit Loss Before Tax 44,094,000.00 23,078,000.00 14,987,000.00
Income Tax Expense Continuing Operations 6,348,000.00 7,082,000.00 1,313,000.00
Profit (loss) 37,746,000.00 15,996,000.00 13,674,000.00
Line item in (usd) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 37,746,000.00 15,996,000.00 13,674,000.00
Adjustments For Finance Costs N/A 33,308,000.00 6,196,000.00 5,463,000.00
Adjustments For Decrease Increase In Inventories N/A -4,934,000.00 -6,153,000.00 -15,016,000.00
Adjustments For Sharebased Payments N/A 6,537,000.00 9,056,000.00 6,392,000.00
Adjustments For Fair Value Gains Losses N/A -69,000.00 -114,000.00 1,185,000.00
Adjustments For Undistributed Profits Of Associates N/A 362,000.00 694,000.00 -1,083,000.00
Other Adjustments For Noncash Items N/A -1,624,000.00 524,000.00 -1,576,000.00
Interest Received Classified As Operating Activities N/A 715,000.00 53,000.00 85,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 2,658,000.00 0.00 1,235,000.00
Cash Flows From Used In Operating Activities N/A 83,626,000.00 37,842,000.00 22,458,000.00
Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities N/A 0.00 4,589,000.00 0.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 4,657,000.00 10,739,000.00 1,376,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 9,060,000.00 3,447,000.00 601,000.00
Cash Flows From Used In Investing Activities N/A -15,629,000.00 -21,305,000.00 5,323,000.00
Proceeds From Issuing Other Equity Instruments N/A 2,791,000.00 4,718,000.00 2,281,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 57,231,000.00 0.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities N/A 2,186,000.00 3,217,000.00 3,311,000.00
Interest Paid Classified As Financing Activities N/A 2,142,000.00 4,448,000.00 3,952,000.00
Cash Flows From Used In Financing Activities N/A 60,686,000.00 -27,947,000.00 -4,982,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 128,683,000.00 -11,410,000.00 22,799,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 2,128,000.00 -1,825,000.00 -7,381,000.00
Cash and cash equivalents 74,348,000.00 205,159,000.00 191,924,000.00 207,342,000.00

Please note that some sums might not add up.

Filings & Publications

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
24.05.23 D.A. Jorn Non-Executive member Other EUR 0.00
21.03.23 P. Sekhri Non-Executive member Other EUR 0.00
27.10.22 P. Sekhri Non-Executive member Buy EUR 12,232.22
27.10.22 M. Pykett Non-Executive member Buy EUR 9,174.40
04.08.22 P. Sekhri Non-Executive member Buy EUR 10,000.23
04.08.22 S. Baert Non-Executive member Buy EUR 7,500.36
25.05.22 J. van der Meijs Non-Executive member Buy EUR 86,490,000.00
25.05.22 P. Sekhri Non-Executive member Buy EUR 9,527.62
25.05.22 M. Pykett Non-Executive member Buy EUR 7,146.86
24.03.22 S. de Vries Non-Executive member Buy EUR 232,249.50

Short Interest


Current short interest

Position Holder Short Interest in Percent Date
Millennium International Management LP 0.51% 15.01.24
Arrowstreet Capital, Limited Partnership 0.51% 21.11.23
Citadel Advisors LLC 0.50% 13.02.24
Marshall Wace LLP 0.50% 22.08.23
Total 2.02%

Capital markets information

ISIN

NL0010391025

LEI

724500DCJ9MPG74JEH91

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Amsterdam

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.